Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia — NIH Grants & Funding

Active and recent NIH-funded research on Hereditary Hemorrhagic Telangiectasia. Data from NIH RePORTER, last 36 months.

MONDO:0019180

NIH-funded research on Hereditary Hemorrhagic Telangiectasia

active grants

institutions

researchers

new in last 12 mo.

$13.6M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(9)

Basic ScienceR01Active

Alk1 ligand requirements for AVM prevention in HHT

HINCK, ANDREW et al.·UNIVERSITY OF PITTSBURGH AT PITTSBURGH·PITTSBURGH, PA

$725,060 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression

Spiekerkoetter, Edda·STANFORD UNIVERSITY·STANFORD, CA

$702,732 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Erasing ill features of arterial endothelial cells in hereditary hemorrhagic telangiectasia

Yao, Yucheng·UNIVERSITY OF CALIFORNIA LOS ANGELES·LOS ANGELES, CA

$390,000 (FY2025)

NIH RePORTER

Basic ScienceR01Completed

Molecular Pathogenesis of Hereditary Hemorrhagic Telangiectasia

Wang, Rong·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$461,208 (FY2024)

NIH RePORTER

Basic ScienceR01Completed

mTOR and VEGFR2 pathways in HHT pathogenesis

MARAMBAUD, PHILIPPE·FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH·MANHASSET, NY

$418,750 (FY2023)

NIH RePORTER

Basic ScienceR01Completed

Molecular mechanisms underlying Arteriovenous Malformations associated with HHT

Meadows, Stryder·TULANE UNIVERSITY OF LOUISIANA·NEW ORLEANS, LA

$380,000 (FY2022)

NIH RePORTER

Basic ScienceF31Completed

UNCOVERING THE COMBINED EFFECTS OF VEGFA AND ANG2 PRO-ANGIOGENIC SIGNALING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA

Bavishi, Shreya·TULANE UNIVERSITY OF LOUISIANA·NEW ORLEANS, LA

$49,538 (FY2025)

NIH RePORTER

Basic ScienceF31Completed

EVALUATING THE IMPACT OF LOSS OF HETEROZYGOSITY ON LOCALIZED AVM FORMATION IN HHT

Bartoletti, Adella·TULANE UNIVERSITY OF LOUISIANA·NEW ORLEANS, LA

$49,538 (FY2025)

NIH RePORTER

Basic ScienceF32Completed

Elucidating mechanisms of hereditary hemorrhagic telangiectasia 2 gene-mediated arteriovenous malformation development via eNOS signaling using in vivo two-photon imaging in a preclinical mouse model

Branyan-Schroer, Kayla·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$14,439 (FY2022)

NIH RePORTER

Translational(3)

TranslationalR01Active

Therapeutic Potential of ALK1 Activating Drugs in HHT Models

MARAMBAUD, PHILIPPE·FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH·MANHASSET, NY

$569,892 (FY2025)

NIH RePORTER

TranslationalK23Active

Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia

Al-Samkari, Hanny·MASSACHUSETTS GENERAL HOSPITAL·BOSTON, MA

$199,800 (FY2025)

NIH RePORTER

TranslationalR01Completed

Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations

MARAMBAUD, PHILIPPE et al.·TULANE UNIVERSITY OF LOUISIANA·NEW ORLEANS, LA

$671,700 (FY2025)

NIH RePORTER

Clinical(2)

ClinicalUH3Completed

1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)

McCrae, Keith·CLEVELAND CLINIC LERNER COM-CWRU·CLEVELAND, OH

$618,148 (FY2023)

NIH RePORTER

ClinicalU24Completed

2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center

Thomas, Sonia·RESEARCH TRIANGLE INSTITUTE·RESEARCH TRIANGLE PARK, NC

$398,234 (FY2023)

NIH RePORTER

NIH Grants & Funding for Hereditary Hemorrhagic Telangiectasia | Kisho | Kisho